Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals

[1]  R. Benedict,et al.  Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study , 2020, Multiple sclerosis.

[2]  K. Blennow,et al.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.

[3]  K. Blennow,et al.  Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.

[4]  Philip S. Insel,et al.  The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults , 2020, Annals of clinical and translational neurology.

[5]  Albert Hofman,et al.  Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study , 2020, Brain : a journal of neurology.

[6]  K. Blennow,et al.  Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia , 2020, Nature Medicine.

[7]  D. Airey,et al.  Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease , 2020 .

[8]  K. Blennow,et al.  Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration , 2020, Nature Medicine.

[9]  Keith A. Johnson,et al.  Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD , 2019, Alzheimer's & Dementia.

[10]  Philip S. Insel,et al.  Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease , 2019, EMBO molecular medicine.

[11]  M. DeMarco,et al.  The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis , 2019, Alzheimer's & dementia.

[12]  James G. Bollinger,et al.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis , 2019, Neurology.

[13]  Keith A. Johnson,et al.  Associations of Physical Activity and β-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. , 2019, JAMA neurology.

[14]  M. Jin,et al.  Role of Neurofilament Light Chain as a Potential Biomarker for Alzheimer's Disease: A Correlative Meta-Analysis , 2019, Front. Aging Neurosci..

[15]  L. Tan,et al.  Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults , 2019, Aging.

[16]  S. Fischer,et al.  Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood. , 2019, Bioanalysis.

[17]  Yanguo Xin,et al.  Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis , 2019, Neuroscience & Biobehavioral Reviews.

[18]  K. Blennow,et al.  Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. , 2019, JAMA neurology.

[19]  Keith A. Johnson,et al.  GERIATRIC DEPRESSION SCALE ITEM-LEVEL ANALYSIS IN RELATION TO IN VIVO CORTICAL AMYLOID AND CEREBRAL REGIONAL TAU IN CLINICALLY NORMAL OLDER ADULTS: FINDINGS FROM THE HARVARD AGING BRAIN STUDY , 2019, Alzheimer's & Dementia.

[20]  K. Blennow,et al.  Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. , 2019, JAMA neurology.

[21]  Zhijun Zhang,et al.  Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease. , 2019, ACS chemical neuroscience.

[22]  C. DeCarli,et al.  Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes , 2019, JAMA neurology.

[23]  A. Kaunitz,et al.  Povidone-iodine 1% is the most effective vaginal antiseptic for preventing post-cesarean endometritis: a systematic review and network metaanalysis. , 2019, American journal of obstetrics and gynecology.

[24]  Keith A. Johnson,et al.  Vascular Risk and β‐Amyloid Are Synergistically Associated with Cortical Tau , 2019, Annals of neurology.

[25]  Nick C Fox,et al.  Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.

[26]  Keith A. Johnson,et al.  The impact of amyloid‐beta and tau on prospective cognitive decline in older individuals , 2018, Annals of neurology.

[27]  José Luis Molinuevo,et al.  Current state of Alzheimer’s fluid biomarkers , 2018, Acta Neuropathologica.

[28]  Wei‐Ju Lee,et al.  Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease , 2018, Scientific Reports.

[29]  Keith A. Johnson,et al.  Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease , 2018, Alzheimer's & Dementia.

[30]  Keith A. Johnson,et al.  Interactive Associations of Vascular Risk and &bgr;-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study , 2018, JAMA Neurology.

[31]  C. Jack,et al.  Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography , 2018, Alzheimer's & Dementia.

[32]  K. Blennow,et al.  Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease , 2018, Alzheimer's Research & Therapy.

[33]  Ludwig Kappos,et al.  Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis , 2018, Brain : a journal of neurology.

[34]  R. Bateman,et al.  Erratum: Tau Kinetics in Neurons and the Human Central Nervous System (Neuron (2018) 97(6) (1284–1298.e7)(S0896627318301363)(10.1016/j.neuron.2018.02.015)) , 2018 .

[35]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[36]  Brian A. Gordon,et al.  Tau Kinetics in Neurons and the Human Central Nervous System , 2018, Neuron.

[37]  D. Selkoe,et al.  Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles , 2018, International journal of molecular sciences.

[38]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[39]  P. Calabresi,et al.  A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation , 2018, Alzheimer's Research & Therapy.

[40]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[41]  R. Sperling,et al.  Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5 , 2017, Alzheimer's & dementia.

[42]  W. Jagust,et al.  Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity , 2017, Nature Communications.

[43]  I. Fyfe.  Alzheimer disease: Neurofilament light in the blood marks Alzheimer degeneration , 2017, Nature Reviews Neurology.

[44]  Reisa A. Sperling,et al.  Harvard Aging Brain Study: Dataset and accessibility , 2017, NeuroImage.

[45]  C. Rowe,et al.  Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study , 2016, The Lancet Neurology.

[46]  M. Staufenbiel,et al.  Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases , 2016, Neuron.

[47]  O. Hansson,et al.  Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography , 2016, Brain : a journal of neurology.

[48]  Cristina Granziera,et al.  Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity , 2016, Multiple sclerosis.

[49]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[50]  K. Blennow,et al.  Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease , 2015, Neurology.

[51]  D. Selkoe,et al.  C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death , 2015, The Journal of Neuroscience.

[52]  Michael W. Weiner,et al.  Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative , 2015, Alzheimer's & Dementia.

[53]  Keith A. Johnson,et al.  Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. , 2014, JAMA neurology.

[54]  J. Clarimón,et al.  Cerebrospinal fluid β‐amyloid and phospho‐tau biomarker interactions affecting brain structure in preclinical Alzheimer disease , 2014, Annals of neurology.

[55]  R. Sperling,et al.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. , 2014, JAMA neurology.

[56]  Keith A. Johnson,et al.  Short-term predictors of clinical progression in the Harvard Aging Brain Study , 2013, Alzheimer's & Dementia.

[57]  Keith A. Johnson,et al.  Short-term predictors of clinical progression in the Harvard Aging Brain Study , 2013, Alzheimer's & Dementia.

[58]  Bruce Fischl,et al.  Within-subject template estimation for unbiased longitudinal image analysis , 2012, NeuroImage.

[59]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[60]  Marylyn D. Ritchie,et al.  A General Framework for Formal Tests of Interaction after Exhaustive Search Methods with Applications to MDR and MDR-PDT , 2010, PloS one.

[61]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[62]  Keith A. Johnson,et al.  Imaging of amyloid burden and distribution in cerebral amyloid angiopathy , 2007, Annals of neurology.

[63]  Y. Pijnenburg,et al.  CSF neurofilament proteins in the differential diagnosis of dementia , 2007, Journal of Neurology, Neurosurgery & Psychiatry.

[64]  Daniel J Bauer,et al.  Probing Interactions in Fixed and Multilevel Regression: Inferential and Graphical Techniques , 2005, Multivariate behavioral research.

[65]  R. Lipton,et al.  Memory impairment on free and cued selective reminding predicts dementia , 2000, Neurology.

[66]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[67]  N. Borhani,et al.  Socioeconomic status, ethnicity, and risk of coronary heart disease. , 1980, American journal of epidemiology.

[68]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[69]  Palmer O. Johnson,et al.  The Johnson-Neyman technique, its theory and application , 1950, Psychometrika.

[70]  C. Jack,et al.  Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community. , 2016, JAMA neurology.

[71]  Maja O’Connor.  LONGITUDINAL STUDY , 2013 .

[72]  W. Brown.  Framingham Heart Study. , 2011, Journal of clinical lipidology.

[73]  D. Wechsler.  WAIS-R manual : Wechsler adult intelligence scale-revised , 1981 .